What top creators are saying about Silence Therapeutics plc(SLNS)
Clinical-stage biotechnology company
4 AI-extracted insights from 3 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 3 scored insights about Silence Therapeutics plc.
The Take
Coverage was mixed but sparse: two sources mentioned a reported Merck KGaA acquisition, while one offered no analysis or investment view. The central thesis was possible acquisition upside, but no offer terms or completion likelihood were provided.
Bull Case
- Reported acquisition: The company was said to be acquired by Merck KGaA, and Martin Shkreli congratulated shareholders (The Shkreli Pill, Martin Shkreli).
Bear Case
- Unclear deal details: No offer price, deal terms, or likelihood of completion were discussed, leaving the reported acquisition unsubstantiated in these insights (The Shkreli Pill, Martin Shkreli).
Catalysts & Targets
- Reported acquisition by Merck KGaA; no price, terms, or completion timing provided.
AI-generated summary. Not investment advice. Learn more.
Top creators covering Silence Therapeutics plc (SLNS)
The 3 sources with the most insights about Silence Therapeutics plc on Kazuha.
Latest insights about Silence Therapeutics plc (SLNS)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Wednesday, October 21, 2026
The company was reported to be acquired by Merck KGaA, but the discussion provided no deal terms or target price.
Monday, October 19, 2026
Mentioned briefly without analysis, valuation, or investment opinion.
The host said the company was to be acquired by Merck KGaA and congratulated shareholders; offer price, deal terms, and completion likelihood were not discussed.
Monday, August 10, 2026
Experienced a significant rally driven by clinical data reporting and considered a cheap stock with upward momentum.
Wednesday, October 21, 2026
The company was reported to be acquired by Merck KGaA, but the discussion provided no deal terms or target price.
Monday, October 19, 2026
Mentioned briefly without analysis, valuation, or investment opinion.
The host said the company was to be acquired by Merck KGaA and congratulated shareholders; offer price, deal terms, and completion likelihood were not discussed.
Monday, August 10, 2026
Experienced a significant rally driven by clinical data reporting and considered a cheap stock with upward momentum.
Discussed alongside Silence Therapeutics plc (SLNS)
Other assets that creators frequently mention in the same content as Silence Therapeutics plc.
Frequently asked
Are top creators bullish or bearish on Silence Therapeutics plc (SLNS) right now?
Mostly bullish. In the last 30 days, 1 insight was bullish, 0 bearish, and 2 neutral about Silence Therapeutics plc (SLNS) across 3 financial sources indexed on Kazuha.
Which podcasters and creators cover Silence Therapeutics plc (SLNS) the most?
The most active sources covering Silence Therapeutics plc (SLNS) on Kazuha are @realmartinshkreli, @theshkrelipill, @shkreliplanet. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Silence Therapeutics plc (SLNS) are on Kazuha?
Kazuha has indexed 4 AI-extracted insights about Silence Therapeutics plc (SLNS) from 3 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Silence Therapeutics plc (SLNS)?
Creators covering Silence Therapeutics plc (SLNS) most frequently also discuss NVDA, IREN, INTC, MU, CRWV. See the "Discussed alongside" section above for full asset pages.